In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The agreement will help ensure wider reach and access to patients in India
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
The appointments come as Andrew Paterson, who has spent 31 years with the company, prepares to retire
Karkinos’ model aims to close both gaps by combining World Health Organization-recommended HPV DNA testing with a digitally enabled continuum of care
34% of pharma firms have already deployed function-specific AI, with drug discovery, clinical trials, and medical writing emerging as key high-impact use cases
The company plans to use this funding to boost AI capabilities, expand vernacular content ecosystem, accelerate product development, and scale user acquisition across Tier 2 and Tier 3 markets
Subscribe To Our Newsletter & Stay Updated
